Literature DB >> 12630634

Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use.

Ali Ahmed1, Richard Maisiak, Richard M Allman, James F DeLong, Robert Farmer.   

Abstract

BACKGROUND: Left ventricular function evaluation and angiotensin-converting enzyme (ACE) inhibitor use are the two basic indicators of heart failure quality of care. In this retrospective follow-up study, we analyzed the association between these two quality indicators and mortality in elderly hospitalized heart failure patients.
METHODS: The patients in our study were older Alabama Medicare beneficiaries discharged with a diagnosis of heart failure in 1994. Cox regression analyses, adjusted for various patient and care characteristics, were performed to estimate the overall mortality rate.
RESULTS: The mean age of the 1,090 patients in our study was 79+/-7.5 years. Both left ventricular function evaluation (hazard ratio, 0.83; 95% confidence interval, 0.705-0.976) and ACE inhibitor use (hazard ratio, 0.77; 95% confidence interval, 0.655-0.905) were associated with a lower 3-year mortality rate. Adjustment for various patient and care characteristics did not alter these associations.
CONCLUSION: Left ventricular function evaluation and ACE inhibitor use were each associated with increased survival time in older Medicare beneficiaries with heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630634     DOI: 10.1097/01.SMJ.0000051271.11872.50

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  6 in total

1.  Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial.

Authors:  Ali Ahmed; Wilbert S Aronow; Jerome L Fleg
Journal:  Am J Ther       Date:  2006 Jul-Aug       Impact factor: 2.688

Review 2.  The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Authors:  Daniela Dobre; Dirk J van Veldhuisen; Mike J L DeJongste; Eric van Sonderen; Olaf H Klungel; Robbert Sanderman; Adelita V Ranchor; Flora M Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

3.  The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old.

Authors:  Inga Klarin; Johan Fastbom; Anders Wimo
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

4.  Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project.

Authors:  Margaret A Feller; Marjan Mujib; Yan Zhang; O James Ekundayo; Inmaculada B Aban; Gregg C Fonarow; Richard M Allman; Ali Ahmed
Journal:  Int J Cardiol       Date:  2011-05-31       Impact factor: 4.164

5.  Adverse drug events and associated factors in heart failure therapy among the very elderly.

Authors:  Richard Sztramko; Vicky Chau; Roger Wong
Journal:  Can Geriatr J       Date:  2011-12-12

6.  Association is not causation: treatment effects cannot be estimated from observational data in heart failure.

Authors:  Christopher J Rush; Ross T Campbell; Pardeep S Jhund; Mark C Petrie; John J V McMurray
Journal:  Eur Heart J       Date:  2018-10-01       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.